Celera, ABI to Split on July 1 | GenomeWeb
NEW YORK (GenomeWeb News) – Applera said today that its two groups, Celera and Applied Biosystems, would be formally separated on July 1.
 
The firm said that the board of directors approved the proposed separation, which will be accomplished by the redemption of all outstanding shares of Celera’s stock. Each share of the current Celera tracking stock will be exchanged for one share of the independent Celera Corp.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.